(13-103) Efficacy and safety of moxifloxacin as an alternative to trimethoprim-sulfamethoxazole for the treatment of patients with pneumonia caused by Stenotrophomonas maltophilia
Wednesday, December 10, 2025
3:15 PM - 4:15 PM
Location: Bayside A, Level 1
Residency Program: Ascension Seton Residency Program Type: PGY1 (Pharmacy) Residency Program Location: Texas
